Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine
Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyond
LOS ANGELES, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB), a TechBio leader focused on next-generation diagnostics, drug discovery, and genetically enhanced cancer therapies, today announced a definitive agreement to merge with BioSymetrics, an artificial intelligence (AI)-driven drug discovery and biomarker identification company. This transformative partnership is designed to enhance Renovaro's data repository, biomarker discovery capabilities, accelerate translational research, and bring precision medicine solutions to cancer and other critical disease areas.
At the core of this collaboration is BioSymetrics' proprietary Elion platform, a cutting-edge AI and machine learning engine that uncovers complex biological relationships to accelerate the discovery of diagnostics and therapeutics. BioSymetrics' Phenograph provides a translational engine that maps human clinical signals to prioritized therapeutic targets and is designed to expedite and improve target and biomarker identification and enable patient stratification and drug repurposing. BioSymetrics' advanced AI in vivo modeling and machine vision systems enable high throughput phenotypic screening, leveraging AI-powered analysis to detect subtle biological responses with unprecedented accuracy. Through in vivo modeling BioSymetrics has amassed an incredible database of proprietary in vivo experimentation, with associated behavioural and morphological analysis. This integrated approach hastens the discovery and validation of transformative therapeutics by bridging computational insights with real-world biological validation, and has enabled platform and analytic partnerships with Janssen, Pfizer, Merck, Supernus Pharma, and Deerfield Cures. By integrating Elion into Renovaro's workflow, the combined entity aims to streamline the translation of biomarker insights into accelerated discovery timelines, enhancing precision in target identification and improving overall research efficiency, ultimately enabling faster and more effective drug discovery and therapeutic development.
'This merger represents a pivotal step in our mission to diagnose cancer and advance precision medicine,' said David Weinstein, CEO of Renovaro. 'By combining our expertise in oncology with BioSymetrics' AI-driven biomarker discovery, we are creating a powerful synergy that will enhance our ability to identify new therapeutic targets, validate diagnostics and accelerate drug development.'
BioSymetrics' AI technology has been instrumental in uncovering novel disease signatures and optimizing precision medicine strategies. Through this merger, Renovaro will gain access to cutting-edge computational tools that enhance the ability to stratify patients, predict treatment responses, and drive more effective therapeutic interventions.
'We are excited to join forces with Renovaro to translate cutting-edge biomarker discoveries into tangible advancements in drug development,' said Anthony Iacovone, CEO of BioSymetrics. 'Our AI-driven Elion platform is significantly impacting precision medicine and by aligning with Renovaro's deep expertise in immunotherapy and oncology, we can accelerate the journey from discovery to clinical application.'
The merger underscores a shared commitment to harnessing AI and data-driven approaches to improve patient outcomes. Moving forward, the combined company will focus on integrating AI-powered biomarker discovery with innovative drug development, ultimately bringing more precise and effective treatments to patients worldwide.
The transaction is expected to close in March 2025, subject to customary closing conditions and regulatory approvals.
For more information, visit www.renovarogroup.com and www.biosymetrics.com.
About BioSymetrics
BioSymetrics is a leading AI-powered drug discovery and data analytics company, focusing on phenotype-based insights to identify novel therapeutics. Its proprietary Elion platform integrates large-scale biological and clinical data to drive innovation in the pharmaceutical and healthcare industries. For more information, visit www.biosymetrics.com.
About RenovaroRenovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development. For more information, visit www.renovarogroup.com.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as 'believes,' 'plans,' 'expects,' 'aims,' 'intends,' 'potential,' or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro's most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Investor RelationsChris TysonExecutive Vice PresidentMZ Group - MZ North America949-491-8235RENB@mzgroup.uswww.mzgroup.us
For media inquiries, please contact:
karen@renovarocube.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 days ago
- Business Wire
Elion Launches Integration of Coalition for Health AI ‘Nutrition Label' Within Vendor Marketplace
NEW YORK--(BUSINESS WIRE)--Elion, the healthcare technology research and intelligence platform for the AI era, announced today a new partnership with the Coalition for Health AI (CHAI), an industry-led coalition committed to developing industry best practices and frameworks to further innovation, safety and security for health AI. As part of this partnership, Elion is beta-launching a new feature: Abridged CHAI model cards now appear on select vendor profiles across its platform. 'As demand for AI adoption accelerates, healthcare leaders need a shared language and set of standards to evaluate solutions responsibly." To facilitate robust evaluation and accelerate adoption of successful AI solutions, CHAI developed an Applied Model Card framework, and recently established its first Model Card registry to support the rapid growth of model cards, or 'nutrition labels' for health AI, used to simplify procurement among health systems and solution providers. CHAI's model cards have created a more standard way to present foundational information about AI solutions, moving from powerpoint presentations to evidence and value-based procurement. Elion cofounder and CEO, Bobby Guelich, announced this new functionality at the CHAI Innovation Summit this week. Providing availability of CHAI's Model Cards through the Elion platform helps provider organizations quickly assess an AI model's intended use, oversight processes, and key performance considerations—all in the context of Elion's broader research and marketplace infrastructure. 'As demand for AI adoption accelerates, healthcare leaders need a shared language and set of standards to evaluate solutions responsibly,' said Guelich. 'CHAI's work in this area is foundational, and we're excited to bring their model cards into the day-to-day workflows of technology decision-makers through Elion's marketplace.' This integration represents the latest step in Elion's mission to equip health systems with the data, tools, and guidance needed to evaluate and implement emerging technologies. The current version includes model cards for a limited set of vendor solutions, with broader availability planned later this year. 'I am thrilled to see our health AI nutrition label advancing effective and responsible health AI,' said Brian Anderson, CHAI's CEO. 'By integrating this with Elion, we are enabling health system AI solution evaluation and allowing decision-makers to easily access Model Cards. CHAI is driven by the expertise of our members and the feedback of our broader health ecosystem and the public. We look forward to working together to unlock the potential benefits of AI, on a foundation of trust, safety, and security." CHAI model cards were designed to enhance transparency and accountability across the AI lifecycle. By displaying key elements of these cards on vendor profiles, Elion aims to bridge the gap between technical documentation and real-world procurement. Learn more about CHAI model cards here. About Elion: Elion is a trusted health IT marketplace and research firm dedicated to empowering healthcare organizations through technology insights and strategic guidance. By bridging the gap between healthcare leaders and innovative solutions, Elion is driving the future of healthcare delivery. For more information, visit: About CHAI: The CHAI (Coalition for Health AI) mission is to be the trusted source of guidelines for Responsible AI in Health. It aims to ensure high-quality care, foster trust among users, and meet the growing healthcare needs. As a coalition bringing together leaders and experts representing health systems, startups, government and patient advocates, CHAI has established working groups focusing on privacy and security, fairness, transparency, usefulness, and safety of AI algorithms.
Yahoo
5 days ago
- Yahoo
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
Expanded IP Portfolio Enhances Data Harmonization and Predictive Analytics Capabilities for High-Growth Biomedical Markets LOS ANGELES, June 03, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), a clinical-stage precision medicine company, today announced that its subsidiary BioSymetrics has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application titled 'Methods, Systems, and Frameworks for Unbiased Data in Drug Discovery Predictions' (Application No. 18/058,752). This patent strengthens Renovaro's AI and machine learning intellectual property portfolio by protecting novel methods for integrating and harmonizing diverse biomedical data sources—such as genomics, electronic health records, imaging, and clinical trial data—into a standardized framework for predictive modeling. 'This patent is a strategic milestone for Renovaro,' said David Weinstein, CEO of Renovaro. 'Together with our previously granted patent, it forms the technological foundation of a scalable, end-to-end platform for AI-powered drug discovery and diagnostics and strengthens our position in the fast-growing market for data-driven therapeutics and clinical insights.' Key Drivers for Renovaro: Expands Foundational IP: Builds on core patent (US 11,379,757), granted in July 2022, which protects machine learning pipeline optimization through advanced feature selection and model tuning. Addresses Real-World Challenges: Tackles integration of siloed and heterogeneous data—an unmet need in pharmaceutical R&D and clinical practice. Enhances Commercial Potential: Enables scalable, distributed computing for biomedical analytics across use cases in rare disease, clinical trials, and personalized medicine. Supports Revenue Growth Strategy: Protects Renovaro's differentiated technology approach, critical for commercial partnerships, licensing opportunities, and platform deployment in life sciences and healthcare. The new patent introduces methods that operate across distributed and parallel computing environments, allowing for real-time, reproducible predictive analytics at scale. This infrastructure is vital as the biopharma industry increases reliance on AI to improve efficiency, reduce costs, and accelerate time-to-market for new therapies. This patent allowance reinforces Renovaro's commitment to building category-defining technology platforms that drive value for patients, partners, and shareholders alike. About Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development, and BioSymetrics which specializes in contingent AI for precision neurology. For more information, visit Forward-Looking StatementsThis release contains forward-looking statements, including those relating to the pending litigation and the proposed merger. These statements involve risks and uncertainties and are subject to change based on future developments. Renovaro undertakes no obligation to update any forward-looking statements except as required by law. Investor Relations Chris TysonExecutive Vice PresidentMZ Group - MZ North America949-491-8235RENB@ For media inquiries, please contact: karen@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Yahoo
Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025
COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ: EVAX) ('Evaxion'), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its first quarter 2025 financial results on Tuesday, May 27, 2025, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged. To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event. To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event. Contact information Evaxion A/SMads KronborgVice President, Investor Relations & Communication+45 53 54 82 96mak@ About EVAXION Evaxion A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients' lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website. Forward-looking statement This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words 'target,' 'believe,' 'expect,' 'hope,' 'aim,' 'intend,' 'may,' 'might,' 'anticipate,' 'contemplate,' 'continue,' 'estimate,' 'plan,' 'potential,' 'predict,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could,' and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at We do not assume any obligation to update any forward-looking statements except as required by law.
